Clinical and therapeutical significances of the cluster and signature based on oxidative stress for osteosarcoma.

bioinformatics immune osteosarcoma oxidative stress prognosis

Journal

Aging
ISSN: 1945-4589
Titre abrégé: Aging (Albany NY)
Pays: United States
ID NLM: 101508617

Informations de publication

Date de publication:
29 Dec 2023
Historique:
received: 01 08 2023
accepted: 13 11 2023
medline: 5 1 2024
pubmed: 5 1 2024
entrez: 5 1 2024
Statut: aheadofprint

Résumé

It is of great clinical significance to find out the ideal tumor biomarkers and therapeutic targets to improve the prognosis of patients with osteosarcoma (OS). Oxidative stress (OXS) can directly target intracellular macromolecules and exhibit dual effects of tumor promotion and suppression. OXS-related genes (OXRGs) were extracted from public databases, including TARGET and GEO. Univariate Cox regression analysis, Random Survival Forest algorithm, and LASSO regression were performed to identify prognostic genes and establish the OXS-signature. The efficacy of the OXS-signature was further evaluated by Kaplan-Meier curves and timeROC package. Evaluation of immunological characteristics was achieved based on ESTIMATE algorithm and ssGSEA. Submap algorithm was used to explore the response to anti-PD1 and anti-CTLA4 therapy for OS. Drug response prediction was conducted by using pRRophetic package. The expression values of related genes in the OXS-signature were detected with PCR assays. Two OXS-clusters were identified for OS, with remarkable differences of clusters presented in prognosis. Kyoto Encyclopedia of Genes Genomes (KEGG) analysis showed that differentially expressed genes (DEGs) between the OXS-clusters were significantly enriched in several immune-related pathways. Patients with lower OS-scores attained better clinical outcomes, and presented more sensitivity to ICB therapy. By contrast, OS patients with higher OS-scores revealed more sensitivity to certain drugs. Furthermore, critical genes, RHBDL2 and CGREF1 from the model, were significantly higher expressed in OS cell lines. Our study identified the clusters and signature based on OXS, which would lay the foundation for molecular experimental research, disease prevention and treatment of OS.

Sections du résumé

BACKGROUND BACKGROUND
It is of great clinical significance to find out the ideal tumor biomarkers and therapeutic targets to improve the prognosis of patients with osteosarcoma (OS). Oxidative stress (OXS) can directly target intracellular macromolecules and exhibit dual effects of tumor promotion and suppression.
METHODS METHODS
OXS-related genes (OXRGs) were extracted from public databases, including TARGET and GEO. Univariate Cox regression analysis, Random Survival Forest algorithm, and LASSO regression were performed to identify prognostic genes and establish the OXS-signature. The efficacy of the OXS-signature was further evaluated by Kaplan-Meier curves and timeROC package. Evaluation of immunological characteristics was achieved based on ESTIMATE algorithm and ssGSEA. Submap algorithm was used to explore the response to anti-PD1 and anti-CTLA4 therapy for OS. Drug response prediction was conducted by using pRRophetic package. The expression values of related genes in the OXS-signature were detected with PCR assays.
RESULTS RESULTS
Two OXS-clusters were identified for OS, with remarkable differences of clusters presented in prognosis. Kyoto Encyclopedia of Genes Genomes (KEGG) analysis showed that differentially expressed genes (DEGs) between the OXS-clusters were significantly enriched in several immune-related pathways. Patients with lower OS-scores attained better clinical outcomes, and presented more sensitivity to ICB therapy. By contrast, OS patients with higher OS-scores revealed more sensitivity to certain drugs. Furthermore, critical genes, RHBDL2 and CGREF1 from the model, were significantly higher expressed in OS cell lines.
CONCLUSIONS CONCLUSIONS
Our study identified the clusters and signature based on OXS, which would lay the foundation for molecular experimental research, disease prevention and treatment of OS.

Identifiants

pubmed: 38180104
pii: 205354
doi: 10.18632/aging.205354
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

15360-15381

Auteurs

Mengjie Ding (M)

Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.

Xianting Ran (X)

Department of Endocrinology and Metabolism, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.

Siyu Qian (S)

Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.

Yue Zhang (Y)

Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.

Zeyuan Wang (Z)

Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.

Meng Dong (M)

Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.

Zhenzhen Yang (Z)

Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.

Shaoxuan Wu (S)

Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.

Xiaoyan Feng (X)

Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.

Jieming Zhang (J)

Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.

Linan Zhu (L)

Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.

Songtao Niu (S)

Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.

Xudong Zhang (X)

Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.

Classifications MeSH